Mar 20, 2009 - Sepracor Inc. today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against those companies who have filed abbreviated new drug applications (ANDAs) with Paragraph IV certifications for generic copies of eszopiclone.
The details can be read here.
No comments:
Post a Comment